Konrad M - Search Results

1

Phase I study of cancer therapy with recombinant interleukin-2 administered by intravenous bolus injection.

Hersh EM, Murray JL, Hong WK, Rosenblum MG, Reuben JM, Weilbaecher R, Sarwal AN, Bradley EC, Konrad M, Arnett FC. Hersh EM, et al. Among authors: konrad m. Biotherapy. 1989;1(3):215-26. doi: 10.1007/BF02170890. Biotherapy. 1989. PMID: 2642025

2

A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.

Krigel RL, Padavic-Shaller KA, Rudolph AR, Litwin S, Konrad M, Bradley EC, Comis RL. Krigel RL, et al. Among authors: konrad m. Cancer Res. 1988 Jul 1;48(13):3875-81. Cancer Res. 1988. PMID: 3132324

3

Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon.

Krigel RL, Padavic-Shaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL. Krigel RL, et al. Among authors: konrad m. J Clin Oncol. 1990 Mar;8(3):460-7. doi: 10.1200/JCO.1990.8.3.460. J Clin Oncol. 1990. PMID: 2407809 Clinical Trial.

4

Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.

Paolozzi F, Zamkoff K, Doyle M, Konrad M, Bradley EC, Rudolph A, Newman N, Gullo J, Scalzo A, Poiesz B. Paolozzi F, et al. Among authors: konrad m. J Biol Response Mod. 1989 Apr;8(2):122-39. J Biol Response Mod. 1989. PMID: 2786553

5

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R. Chapman PB, et al. Among authors: konrad m. Invest New Drugs. 1988 Sep;6(3):179-88. doi: 10.1007/BF00175395. Invest New Drugs. 1988. PMID: 3263958

6

Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.

Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL, et al. Kolitz JE, et al. Among authors: konrad m. J Biol Response Mod. 1987 Aug;6(4):412-29. J Biol Response Mod. 1987. PMID: 3498011

7

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al. Kolitz JE, et al. Among authors: konrad m. J Biol Response Mod. 1988 Oct;7(5):457-72. J Biol Response Mod. 1988. PMID: 3263471

8

Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

Whitehead RP, Ward D, Hemingway L, Hemstreet GP 3rd, Bradley E, Konrad M. Whitehead RP, et al. Among authors: konrad m. Cancer Res. 1990 Oct 15;50(20):6708-15. Cancer Res. 1990. PMID: 2208137

9

A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy.

Zamkoff KW, Hudson J, Groves ES, Childs A, Konrad M, Rudolph AR. Zamkoff KW, et al. Among authors: konrad m. J Immunother (1991). 1992 Feb;11(2):103-10. doi: 10.1097/00002371-199202000-00004. J Immunother (1991). 1992. PMID: 1571332

10

Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES. Weiner LM, et al. Among authors: konrad ms. Cancer Res. 1989 Jul 15;49(14):4062-7. Cancer Res. 1989. PMID: 2786751 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

500 results

Search Page

Filters